Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Cited by (983)

Items 401–500 of 983

1. A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
   Peiling Xie, Rui Fang An, Shibo Yu, Jianjun He, Huimin Zhang · 2021 · Journal of Translational Medicine
2. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
   Feng Zhang, Yuyang Wang, Fangfang Yang, Yuming Zhang, Man Jiang, Xiaochun Zhang · 2022 · Cancer Management and Research
3. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
   Yingjia Sun, Ziming Li, Hong Jian, Liliang Xia, Shun Lü · 2022 · Journal of Clinical Medicine
4. The prognostic index of m7G-related genes in CRC correlates with immune infiltration
   Xinkun Huang, Bin Zhu, Chenyu Qian, Ying Feng · 2022 · Scientific Reports
5. Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer
   Artūras Dobilas, Yilun Chen, Christian Brueffer, Pia Leandersson, Lao H. Saal, Christer Borgfeldt · 2023 · Cancer Genomics & Proteomics
6. Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
   Le‐Tian Huang, Jie‐Tao Ma, Shuling Zhang, Xiaohan Li, Li Sun, Wei Jing, Jianzhu Zhao, Yan-Ru Wang, Cheng‐Bo Han · 2019 · Frontiers in Oncology
7. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
   Richard Kenneth Yang, Yun Qing, Fatima Zahra Jelloul, Mark J. Routbort, Peng Wang, Kenna R Mills Shaw, Jiexin Zhang, Jack Lee, Leonard Jeffrey Medeiros, Scott Kopetz et al. · 2020 · Oncotarget
8. Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication
   Wei Wang, Meihong Wu, Minglu Liu, Zhengqing Yan, Guoqiang Wang, Dongliang Mao, Mei Wang · 2020 · Journal for ImmunoTherapy of Cancer
9. Biomarkers of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Beyond PD-L1
   Luis Cabezón‐Gutiérrez, Sara Custodio‐Cabello, Magda Palka-Kotlowska, Soledad Alonso Viteri, Parham Khosravi‐Shahi · 2021 · Clinical Lung Cancer
10. Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
    Takashi Ito, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, Kenji Ube, Yoshiaki Mori, Kana Watanabe et al. · 2021 · Thoracic Cancer
11. Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
    Francesca Jacobs, Massimiliano Cani, Umberto Malapelle, Silvia Novello, Valerio Maria Napoli, Paolo Bironzo · 2021 · Cancers
12. Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma
    Stéphane Renaud, Joseph Seitlinger, Francesco Guerrera, Jérémie Reeb, Michèle Beau‐Faller, Anne‐Claire Voegeli, Joëlle Siat, Christelle Clément-Duchêne, Angelica I. Tiotiu, Nicola Santelmo et al. · 2018 · Annals of Surgical Oncology
13. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
    Cristina Bagacean, Adrian Tempescul, David Ternant, Anne Banet, Nathalie Douet‐Guilbert, Anne Bordron, Boutahar Bendaoud, Hussam Saad, Mihnea Zdrenghea, Christian Berthou et al. · 2019 · Journal for ImmunoTherapy of Cancer
14. Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer
    Hui Liu, Qiyuan Hong, Shuohan Zheng, Meifang Zhang, Ling Cai · 2024 · Lung Cancer
15. Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy
    Wenjing Yin, Si-Cong Ma, Zhong‐Yi Dong, Meng Xu, Wu Mao · 2021 · Cancer Management and Research
16. Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
    Natalia Krzyżanowska, Paweł Adam Krawczyk, Kamila Wojas‐Krawczyk, Tomasz Kucharczyk, Janusz Milanowski · 2022 · Cells
17. Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer
    Simone Stensgaard, Astrid Thomsen, Sofie Helstrup, Peter Meldgaard, Boe Sandahl Sørensen · 2023 · Translational Lung Cancer Research
18. Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization
    Rachelle Mendoza, Heather Chen, Pankhuri Wanjari, Peng Wang, Emily Symes, Daniel N. Johnson, Ward A. Reeves, Jeffrey S. Mueller, Tatjana Antic, Anna Biernacka · 2024 · Cancer Medicine
19. KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non–small-cell Lung Cancer
    Stéphane Renaud, Francesco Guerrera, Joseph Seitlinger, Jérémie Reeb, Anne‐Claire Voegeli, Michèle Legrain, B. Mennecier, Nicola Santelmo, Pierre‐Emmanuel Falcoz, Élisabeth Quoix et al. · 2018 · Clinical Lung Cancer
20. Role of tumor gene mutations in treatment response to immune checkpoint blockades
    Manni Wang, Yu Liu, Xiawei Wei, Yuquan Wei · 2019 · Precision Clinical Medicine
21. Targeting Mutant KRAS for Anticancer Therapy
    Fengqian Chen, Martin Prince Alphonse, Yan Liu, Qi Liu · 2019 · Current Topics in Medicinal Chemistry
22. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non–Small-Cell Lung Cancer
    Nasha Zhang, Jia Wu, Jinming Yu, Hui Zhu, Ming Yang, Ruijiang Li · 2019 · Clinical Lung Cancer
23. A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma
    Luochengling Xiang, Xiao Fu, Xiao Wang, Wenyuan Li, Xiaoqiang Zheng, Kejun Nan, Tao Tian · 2020 · Frontiers in Oncology
24. KRAS oncogene may be another target conquered in non‐small cell lung cancer ( NSCLC )
    Hanxiao Chen, Jun Zhao · 2020 · Thoracic Cancer
25. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
    Dejun Zeng, Zhengyang Hu, Yanjun Yi, Valeria Besskaya, Guangyao Shan, Zhencong Chen, Cheng Zhan, Miao Lin, Zongwu Lin, Qun Wang · 2021 · BMC Pulmonary Medicine
26. High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma
    Jianping Song, Xue-Zhi Liu, Qian Chen, Yanfeng Liu · 2022 · World Journal of Clinical Cases
27. JAK3 A573V and JAK3 M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway
    Ning Lou, Mengwei Yang, Zucheng Xie, Ruyun Gao, Lei Zhang, Le Min Tang, Jiarui Yao, Xiaohong Han, Yuankai Shi · 2025 · Journal for ImmunoTherapy of Cancer
28. Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
    Muqi Shi, Yan Wang, Weidong Tang, Xiaohong Cui, Han Jiang Wu, Yijie Tang, Peng Wang, Wei Wu, Haijian Zhang · 2020 · Annals of Translational Medicine
29. Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers
    Debbie Moss, Christopher K. McCann, Emma M. Kerr · 2022 · Science Signaling
30. Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study
    Lian Yu, Jianlin Xu, Rong Qiao, Hua Zhong, Wolfgang Michael Brueckl, Runbo Zhong · 2023 · Translational Lung Cancer Research
31. The Puzzle of Predicting Response to Immune Checkpoint Blockade
    Mykola I. Onyshchenko · 2018 · EBioMedicine
32. Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer
    Zhu Lingling, Jiewei Liu, Wang Li, Yan Danli, Zhou Jie, Wen Li, Dan Pu, Peng Lei, Zhou Qinghua · 2020 · Pathology - Research and Practice
33. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
    Jingjing Fan, Xiangfeng Shen, Yishu Wang, Honglan Zhou, Guolong Liu, Yulin Li, Zhi‐Xiang Xu · 2020 · Biomedicine & Pharmacotherapy
34. Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico
    Ruifang Zheng, Zhiwei Yin, Albert Alhatem, Derek Lyle, Bei You, Andrew S. Jiang, Dongfang Liu, Zsolt Jobbágy, Qing Wang, Seena C. Aisner et al. · 2020 · Cancers
35. A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients
    Yanqing Liu, Aihua Wu, Xinjian Li, Shanshan Wang, Shuyu Fang, Yijun Mo · 2021 · Asian Journal of Surgery
36. Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
    Jiaxin Li, Runze Li, Lin-Rui Ma, Peng Wang, Donghan Xu, Jie Huang, Li-Qi Li, Ling Long Tang, Ying Xie, Elaine Lai‐Han Leung et al. · 2022 · Frontiers in Pharmacology
37. Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
    Yunzhen Wang, Sha Huang, Xiangwei Feng, Wangjue Xu, Raojun Luo, Ziyi Zhu, Qingxin Zeng, Zhengfu He · 2023 · Frontiers in Oncology
38. Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants
    Yunfang Yu, Dagui Lin, Anlin Li, Yongjian Chen, Qiyun Ou, Hai Hu, Herui Yao · 2020 · JAMA Network Open
39. Explainable Transformer-Based Neural Network for the Prediction of Survival Outcomes in Non-Small Cell Lung Cancer (NSCLC)
    Elly Kipkogei, Gustavo Arango-Argoty, Ioannis Kagiampakis, Arijit Patra, Etai Jacob · 2021 · medRxiv
40. Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis
    Yubo Jiang, Gang Mai, Xiaokai Zhao, Meng Xiong Tang, Pengmin Yang, Qian Cheng, He Tian, Zuoxing Niu, Xintao Wang, Jiao Wang et al. · 2025 · npj Precision Oncology
41. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation
    Jing Fu, Yaonan Li, Cuidan Li, Yuyang Tong, Mengyuan Li, Shundong Cang · 2021 · Translational Cancer Research
42. A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer
    Liu, Yi, Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Changchun, Jilin, China, Cheng, Long, Song, Xiangyang, Li, Chao, Zhang, Jiantao, Wang, Lei, Department of Orthopedics, The First Hospital of Jilin University, Changchun, Jilin, China, Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Street Xinmin 71, Changchun, China · 2022 · Mathematical Biosciences and Engineering
43. An exploration of gastric cancer with heterogeneous mismatch repair status
    Xinyu Wang, Kang Jiang, Yajie Hu, Xinya Zhao, Lisha Yin, Xinting Diao, Xiuli Ma, Yu Xu, Yuezong Bai, Yan Zhang et al. · 2023 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
44. Real‐world retrospective study of KRAS mutations in advanced non–small cell lung cancer in the era of immunotherapy
    Paolo Bironzo, Massimiliano Cani, Francesca Jacobs, Valerio Maria Napoli, Angela Listì, Francesco Passiglia, Luisella Righi, Massimo Di Maïo, Silvia Novello, Giorgio V. Scagliotti · 2023 · Cancer
45. Biomarker for personalized immunotherapy
    Si‐Yang Maggie Liu, Yi-Long Lung Cancer Wu · 2019 · Translational Lung Cancer Research
46. Computed Tomography Texture Analysis of Response to Second-Line Nivolumab in Metastatic Non-Small Cell Lung Cancer
    Rahul Ladwa, Kate Elizabeth Roberts, Connor Gerard O’Leary, Nicole Maggacis, Kenneth John O'Byrne, Kenneth Alan Miles · 2020 · Lung Cancer Management
47. De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
    Si-Cong Ma, Hongbo Zhu, Jian Wang, Yan-Pei Zhang, Xue‐Jun Guo, Li-Li Long, Ze-Qin Guo, Dehua Wu, Zhong‐Yi Dong, Xue Bai · 2021 · Frontiers in Oncology
48. MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
    Katsuhiro Yoshimura, Yusuke Inoue, Naoki Inui, Masato Karayama, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto et al. · 2021 · JTO Clinical and Research Reports
49. Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
    Yunchang Li, Lanlin Hu, Xinhao Peng, Huasheng Xu, Bo Tang, Chuan Shan Xu · 2022 · Cancer Drug Resistance
50. Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
    Christophe Bontoux, Véronique Hofman, Patrick Brest, Marius Ilié, Baharia Mograbi, Paul M Hofman · 2022 · Cancers
51. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy
    Joseph Nicholas Bodor, Jessica Ruth Bauman, Elizabeth A. Handorf, Eric A. Ross, Margie L. Clapper, Joseph Treat · 2022 · Journal of Cancer Research and Clinical Oncology
52. Targeting KRAS : Crossroads of Signaling and Immune Inhibition
    Shumei Kato, Yu Fujiwara, David S. Hong · 2022 · Journal of Immunotherapy and Precision Oncology
53. High SERPINH1 expression predicts poor prognosis in lung adenocarcinoma
    Hailing Zhang, Xiaodi Yan, Hongmei Gu, Qiang Xue, Xiancheng Liu · 2022 · Journal of Thoracic Disease
54. Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
    Danyang Sun, Junxun Ma, Jinliang Wang, Fan Zhang, Lijie Wang, Sujie Zhang, Guang‐Ying Chen, Xiaoyan Li, Wushuang Du, Pengfei Cui et al. · 2018 · Therapeutics and Clinical Risk Management
55. MeImmS: Predict Clinical Benefit of Anti-PD-1/PD-L1 Treatments Based on DNA Methylation in Non-small Cell Lung Cancer
    Shipeng Shang, Xin Li, Yue Gao, Shuang Guo, Dailin Sun, Hanxiao Zhou, Yue Sun, Peng Wang, Hui Zhi, Jing Bai et al. · 2021 · Frontiers in Genetics
56. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer
    Zhang, Feng, Zhong, Wenhui, Li, Honghao, Huang, Kaijun, Yu, Min, Liu, Yubin · 2021 · Frontiers in Cell and Developmental Biology
57. Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China
    Liyuan Wu, Wei Rao, Lei Guo, Fanshuang Zhang, Weihua Li, Jianming Ying · 2025 · Journal of Cancer Research and Clinical Oncology
58. CNOT4 enhances the efficacy of anti‐PD‐1 immunotherapy in a model of non‐small cell lung cancer
    Biao Zhang, Song Hee Han, Haitao Ma, Shaomu Chen · 2020 · FEBS Open Bio
59. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer
    Matthew Z. Guo, Joseph Christopher Murray, Paola Ghanem, Khinh Ranh Voong, Russell Kenneth Hales, David S. Ettinger, Vincent K. L. Lam, Christine L. Hann, Patrick M. Forde, Julie Renee Brahmer et al. · 2022 · Clinical Lung Cancer
60. Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients
    Jingya Liu, Jianing Gao · 2023 · European Journal of Cancer Prevention
61. Machine Learning Revealed Ferroptosis Features and Ferroptosis-Related Gene-Based Immune Microenvironment in Lung Adenocarcinoma
    Lianxiang Luo, Xinming Chen, Fangfang Huang · 2022 · Chemico-Biological Interactions
62. Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
    Jie Yao, Xuwen Lin, Xin Zhang, Mei Xie, Xidong Ma, Xinyu Bao, Jialin Song, Yiran Liang, Qiqi Wang, Xinying Xue · 2024 · Human Vaccines & Immunotherapeutics
63. PD-L1 Expression Varies in Thyroid Cancer Types and Is Associated with Decreased Progression Free Survival (PFS) in Patients with Anaplastic Thyroid Cancer
    Leila A. Shobab, Deema Al-Souri, Liza Mathews, Matthew McCoy, William Kuenstner, Gretchen K. Hubbard, Sonam Kumari, Jiling Chou, Wen Lee, Jennifer E. Rosen et al. · 2024 · Cancers
64. Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions
    Nadia Ghazali, Marina Chiara Garassino, Natasha B. Leighl, Christine M. Bestvina · 2025 · Therapeutic Advances in Medical Oncology
65. Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression
    Chen Chen, Xi Chen, Yanling Zhang, Qijun Zhang, Haixia Shi · 2025 · Frontiers in Oncology
66. ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer
    Timm M. Reißig, Linda Sara, Saskia C. Ting, Henning Reis, Martin Metzenmacher, Wilfried Eberhardt, Gregor Zaun, Thomas Herold, Clemens Aigner, Kaid Darwiche et al. · 2020 · Lung Cancer
67. Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
    Wei Nie, Lu Gan, Xin Wang, Kai Gu, Fang-Fei Qian, Min-Juan Hu, Ding Zhang, Shi-Qing Chen, Jun Lü, Shu-Hui Cao et al. · 2021 · OncoImmunology
68. Eleven immune-gene pairs signature associated with TP53 predicting the overall survival of gastric cancer: a retrospective analysis of large sample and multicenter from public database
    Junyu Huo, Li-Qun Wu, Yun-jin Zang · 2021 · Journal of Translational Medicine
69. Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
    Pamela Abdayem, David Planchard · 2021 · European Respiratory Review
70. Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer
    Qiushi Feng, Dandan Song, Haiying Zhou, Hui Lu, Xiaosheng Wang · 2021 · Life Sciences
71. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma
    Yefeng Shen, Shao‐Chun Wang, Yuanzhou Wu · 2022 · Cells
72. A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab
    Yinchen Shen, Jiaqi Li, Huiping Qiang, Yuqiong Lei, Qing Hua Chang, Runbo Zhong, Giulia Maria Stella, Francesco Gelsomino, Yeon Wook Kim, Afaf Abed et al. · 2022 · Translational Lung Cancer Research
73. Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy
    Ya‐Ru Miao, Chunjie Liu, Hui Hu, Mei Yang, An‐Yuan Guo · 2022 · Cells
74. Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report
    Pan Yang, Fu Xiong, Lin Yong, Peiqiang Liang, Chunlan Tang · 2023 · Translational Cancer Research
75. Immune Oncology Biomarkers in Lung Cancer: an Overview
    Camille Travert, F. Barlesi, L. Greillier, P. Tomasini · 2020 · Current Oncology Reports
76. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer
    Kaitang Huang, Meiling Hu, Jiayun Chen, Jinfen Wei, Jingxin Qin, Shudai Lin, Hongli Du · 2021 · International Journal of Molecular Sciences
77. Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non‐small cell lung cancer
    Jin Duan, Guoli Lv, Nanye Zhu, Xin Chen, Yang Washington Shao, Yong Liu, Zhao Wei, Yunfei Shi · 2022 · Thoracic Cancer
78. NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer
    Xiaoyang Gong, Haibin Chen, Liqing Zhang, Dongsheng Chen, Wang Li, Donghui Chen, Jin Rui Xu, Han Peng Zhou, Lele Zhao, Yun-jie Song et al. · 2022 · Frontiers in Immunology
79. Pan‐cancer efficacy and safety of anlotinib plus PD ‐1 inhibitor in refractory solid tumor: A single‐arm, open‐label, phase II trial
    Bao‐Dong Qin, Xiao‐Dong Jiao, Zhan Wang, Ke Liu, Ying Wu, Yan Ling, Shiqi Chen, Xue Zhong, Xiao‐Peng Duan, Wenxing Qin et al. · 2023 · International Journal of Cancer
80. Anticancer therapeutic strategies for targeting mutant p53-Y220C
    Vitaly V. Chasov, Damir Davletshin, Elvina Gilyazova, Regina Mirgayazova, Anna A. Kudriaeva, Raniya Khadiullina, Youyong Yuan, Emil Bulatov · 2023 · Journal of Biomedical Research
81. Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR -Mutant Non–Small Cell Lung Cancer
    Simeng Wang, Jia-Cheng Lai, Yu Li, Chengfang Tang, Jiajia Lu, Min Sung Han, Xianjiang Ye, Lina Jia, Wei Cui, Jingyu Yang et al. · 2024 · Cancer Research
82. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review
    Scarlet B. Urtecho, Leonardo Provenzano, Andrea Spagnoletti, Achille Bottiglieri, Chiara Carlotta Pircher, Giacomo Massa, Caterina Sposetti, Claudia Proto, Marta Brambilla, Mario Alberto Occhipinti et al. · 2024 · Lung Cancer
83. Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies
    Arunabh Arandhara, Pallabi Bhuyan, Bhrigu Kumar Das · 2025 · Discover Oncology
84. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas
    Richard S.P. Huang, James Haberberger, Lukas Harries, Eric Allan Severson, Daniel L. Duncan, N. Lynn Ferguson, Amanda C. Hemmerich, Claire I. Edgerly, Karthikeyan Murugesan, Jinpeng Xiao et al. · 2021 · The Oncologist
85. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
    Lei Sun, Man Li, Ling Deng, Yuchun Niu, Yichun Tang, Yu Wang, Linlang Guo · 2021 · Frontiers in Pharmacology
86. Lipid metabolism-related gene prognostic index (LMRGPI) reveals distinct prognosis and treatment patterns for patients with early-stage pulmonary adenocarcinoma
    Aimin Jiang, Xue Chen, Haoran Zheng, Na Liu, Qianqian Ding, Yimeng Li, Chaoxin Fan, Xiao Fu, Xuan Liang, Tao Tian et al. · 2022 · International Journal of Medical Sciences
87. Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients
    Taohua Yue, Yunlong Cai, Jing Zhu, Yucun Liu, Shanwen Chen, Pengyuan Wang, Long Rong · 2023 · Frontiers in Immunology
88. Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies
    Minggui Pan, Chen Jiang, Zheyang Zhang, Ninah S. Achacoso, Aleyda V. Solorzano, Pam Tse, Elaine H. Chung, Jennifer Marie Suga, Sachdev P. Thomas, Laurel A. Habel · 2023 · Cancers
89. REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression
    Si Sun, Zhihuang Hu, Shenglin Huang, Xun Ye, Jialei Wang, Jianhua Chang, Xianghua Wu, Qifeng Wang, Lanlin Zhang, Xingjiang Hu et al. · 2019 · Journal of Cancer Research and Clinical Oncology
90. Effect of p53 activation through targeting MDM2/MDM4 heterodimer on T regulatory and effector cells in the peripheral blood of Type 1 diabetes patients
    Marsha Pellegrino, Gianandrea Traversi, Andrea Arena, Marco Cappa, M. Manuela Rosado, Marco Andreani, Domenico Vittorio Delfino, Fabiola Moretti, Alessandra Fierabracci · 2020 · PLoS ONE
91. Comprehensive analysis of microenvironment-related genes in lung adenocarcinoma
    Ye Tao, Bin Liang, Yunhui Li · 2020 · Future Oncology
92. Immune signature of tumor-infiltrating immune cells predicts the prognosis and therapeutic effects in squamous cell carcinoma
    Yun Che, Zhiwen Luo, Chaoqi Zhang, Nan Sun, Shugeng Gao, Jie He · 2020 · International Immunopharmacology
93. A TP53-based immune prognostic model for muscle-invasive bladder cancer
    Hongyan Li, Huayi Lü, Wanli Cui, Yufan Huang, Xuefei Jin · 2020 · Aging
94. Characterization of Tumor Microenvironment in Lung Adenocarcinoma Identifies Immune Signatures to Predict Clinical Outcomes and Therapeutic Responses
    Donglai Chen, Yifei Wang, Xi Zhang, Qifeng Ding, Xiao‐Fan Wang, Yuhang Xue, Wei Wang, Yiming Mao, Chang Chen, Yongbing Chen · 2021 · Frontiers in Oncology
95. The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer
    Zuobing Chen, Canping Chen, Lin Li, Tianfang Zhang, Xiaosheng Wang · 2021 · Computational and Structural Biotechnology Journal
96. Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
    Xiaojin Guo, He Du, Jiayu Li, Meng‐Hang Yang, Anweng Xiong, Haiping Zhang, Fengying Wu · 2022 · Cancer Drug Resistance
97. Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Yanan Cui, Xinyin Liu, Yuemin Wu, Liang Xiao, Jiali Dai, Zhihong Zhang, Renhua Guo · 2022 · Frontiers in Oncology
98. The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody
    Chenxi Liu, Sihui Zhu, Yanbing Dong, Jie Shao, Baorui Liu, Jie Shen · 2022 · Frontiers in Immunology
99. Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53
    Douglas W. Brown, Perrin H. Beatty, John D. Lewis · 2022 · Cancers
100. Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial
     Xiangrui Meng, Xiuli Yang, Yonggui Hong, Wenkang Wang, Zhiye Zhang, Jin Xia, Yunfang Chen, Yue Zhou, Taiying Lu, Min Seob Song et al. · 2025 · Molecular Cancer